What is the Berotralstat Dihydrochloride Crystalline Form Patent?
Berotralstat dihydrochloride, marketed as Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE). A key aspect of its commercialization involves patent protection for specific crystalline forms of the drug. For instance, U.S. Patent No. 10,973,786, titled "Crystalline Forms of Berotralstat Dihydrochloride," describes and claims a particular crystalline form of berotralstat dihydrochloride. [1] This patent, among others, is crucial for securing market exclusivity for the drug.
When Does the Berotralstat Dihydrochloride Crystalline Form Patent Expire?
The expiration of patents for crystalline forms, like U.S. Patent No. 10,973,786, is a critical factor in determining when generic versions of Orladeyo might become available. Patent expiration dates are tracked by resources such as DrugPatentWatch.com. [2] The specific expiration date for the '786 patent would need to be consulted on such platforms, but generally, patents have a term of 20 years from the filing date, though extensions are possible.
Why Are Companies Challenging This Patent?
Generic drug manufacturers frequently challenge existing patents to gain early market entry. Challenges can involve seeking to invalidate the patent, asserting that it should not have been granted, or arguing that their proposed generic product does not infringe the patent claims. Such challenges are part of the competitive landscape aimed at reducing the period of market exclusivity enjoyed by the innovator drug.
How Does Berotralstat Dihydrochloride Work?
Berotralstat is a plasma kallikrein inhibitor. By inhibiting plasma kallikrein, it prevents the overproduction of bradykinin, a substance implicated in the swelling characteristic of HAE attacks. This mechanism of action differentiates it from other HAE treatments that may target different pathways.
What Are the Clinical Data for Berotralstat?
Clinical trials have demonstrated the efficacy of berotralstat in reducing the frequency of HAE attacks. Studies have shown statistically significant reductions in monthly attack rates compared to placebo. The drug is taken orally, offering a convenient dosing regimen for patients.
What Side Effects Are Patients Asking About?
Common side effects reported with berotralstat include upper respiratory tract infections, diarrhea, nausea, abdominal pain, and vomiting. Patients and healthcare providers monitor for these and other potential adverse events to ensure the safe use of the medication.
Who Manufactures Berotralstat?
Berotralstat is developed and marketed by BioCryst Pharmaceuticals. [3] They hold the intellectual property rights and are responsible for its clinical development, manufacturing, and commercialization.
What Are the Alternatives to Berotralstat for HAE?
Hereditary angioedema can be treated with various medications, including both acute attack treatments and prophylactic (preventive) therapies. Alternatives include C1 esterase inhibitor (C1-INH) replacement therapies (both intravenous and subcutaneous), icatibant (a bradykinin B2 receptor antagonist), and lanadelumab (a monoclonal antibody that inhibits plasma kallikrein). Berotralstat offers an oral prophylactic option, distinguishing it from many other available treatments.
Can Biosimilars Enter Before Patent Expiry?
For small molecule drugs like berotralstat dihydrochloride, the concept of "biosimilars" does not directly apply. Biosimilars are highly similar versions of complex biologic drugs. Instead, generic versions of small molecule drugs enter the market after patent expiration and regulatory approval by agencies like the U.S. Food and Drug Administration (FDA). Generic competition is typically not permitted until the relevant patents and other exclusivities have expired.
Sources:
[1] https://patents.google.com/patent/US10973786B2/en
[2] https://drugpatentwatch.com/
[3] https://www.biocryst.com/